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Abstract
Background High milk intake has been associated with cardio-metabolic risk. We conducted a Mendelian Randomization
(MR) study to obtain evidence for the causal relationship between milk consumption and cardio-metabolic traits using the
lactase persistence (LCT-13910 C > T, rs4988235) variant as an instrumental variable.
Methods We tested the association of LCT genotype with milk consumption (for validation) and with cardio-metabolic traits (for a
possible causal association) in a meta-analysis of the data from three large-scale population-based studies (1958 British Birth
Cohort, Health and Retirement study, and UK Biobank) with up to 417,236 participants and using summary statistics from consortia
meta-analyses on intermediate traits (N= 123,665–697,307) and extended to cover disease endpoints (N= 86,995–149,821).
Results In the UK Biobank, carriers of ‘T’ allele of LCT variant were more likely to consume milk (P= 7.02 × 10−14). In
meta-analysis including UK Biobank, the 1958BC, the HRS, and consortia-based studies, under an additive model, ‘T’ allele
was associated with higher body mass index (BMI) (Pmeta-analysis= 4.68 × 10−12) and lower total cholesterol (TC) (P=
2.40 × 10−36), low-density lipoprotein cholesterol (LDL-C) (P= 2.08 × 10−26) and high-density lipoprotein cholesterol
(HDL-C) (P= 9.40 × 10−13). In consortia meta-analyses, ‘T’ allele was associated with a lower risk of coronary artery
disease (OR:0.86, 95% CI:0.75–0.99) but not with type 2 diabetes (OR:1.06, 95% CI:0.97–1.16). Furthermore, the two-
sample MR analysis showed a causal association between genetically instrumented milk intake and higher BMI (P= 3.60 ×
10−5) and body fat (total body fat, leg fat, arm fat and trunk fat; P < 1.37 × 10−6) and lower LDL-C (P= 3.60 × 10−6), TC
(P= 1.90 × 10−6) and HDL-C (P= 3.00 × 10−5).
Conclusions Our large-scale MR study provides genetic evidence for the association of milk consumption with higher BMI
but lower serum cholesterol levels. These data suggest no need to limit milk intakes with respect to cardiovascular disease
risk, with the suggested benefits requiring confirmation in further studies.
Background
Obesity, hypertension, dyslipidaemias and hyperglycae-
mia are all strong contributors’ to cardio-metabolic dis-
eases, which are the major causes of morbidity and
mortality worldwide [1–3]. Diet is a major determinant of
cardio-metabolic diseases [4] and several studies have
* Elina Hyppönen
elina.hypponen@unisa.edu.au
1 Hugh Sinclair Unit of Human Nutrition, University of Reading,
Reading, UK
2 Population, Policy and Practice, UCL Institute of Child Health,
London, UK
3 Institute for Food, Nutrition, and Health, University of Reading,
Reading, UK
4 Australian Centre for Precision Health, Unit of Clinical and Health
Sciences, University of South Australia, Adelaide, SA, Australia
5 Section of Epidemiology and Biostatistics, School of Population
Health, University of Auckland, Auckland, New Zealand
6 South Australian Health and Medical Research Institute,
Adelaide, SA, Australia
Supplementary information The online version contains
















shown associations between dairy and milk consumption
and cardio-metabolic risk factors [5–10]. High fat dairy
products can lead to adverse effects on cardiovascular risk
by increasing the intake of saturated fat and cholesterol
which have been shown to increase blood cholesterol and
subsequent risk of cardiovascular diseases (CVDs)
[11, 12]. In addition, milk is a major source of calcium
and a risk factor for arterial calcification [13]. Despite
these proposed adverse effects, a reduced risk of CVDs
was reported for consumption of milk and low-fat dairy
products in large scale meta-analysis of data from nine
studies (N= 57,256) [8]. The findings from randomised
controlled trials (RCTs) have been inconsistent [14],
failing to provide causal evidence either for a beneficial or
adverse causal association.
The lactase enzyme, which is responsible for the diges-
tion of milk sugar lactose, is encoded by the lactase (LCT)
gene. A functional single nucleotide polymorphism (SNP),
−13910 C/T (rs4988235), located upstream of the LCT
gene, has been shown to affect the transcription of the
enzyme and control the distribution of lactase phenotypes in
human populations. The ‘T’ allele of the SNP rs4988235 is
associated with lactase persistence (LP) and has been shown
to increase the LCT gene promoter activity after binding
transcription factors [15]. Given the functional impact of
this SNP on the digestion of milk sugar lactose, the SNP
rs4988235 has been used as proxy for milk intake in
Mendelian randomization (MR) studies that examined the
relationship between milk intake and diseases [16–18].
Recent studies have demonstrated a causal relationship
between higher dairy intake and higher body mass index
(BMI) [19, 20] but not CVD-related outcomes [21]. Given
the discrepancies, we set out to comprehensively examine
the causal association between milk consumption and CVD,
Type 2 Diabetes (T2D) and cardio-metabolic risk factors,
including measures of adiposity, blood pressure, and mar-
kers of chronic inflammation, lipid and glucose metabolism.
Our MR study included meta-analysis of the data in up to
417,236 individuals from three large population-based stu-
dies [22–24], and summary statistics data from several large
consortia meta-analyses (N up to 1,486,984) [25–29].
Methods
Study populations
The full details of the three study populations [the 1958
British Birth cohort (1958BC), Health Retirement Study
(HRS) and UK Biobank] are included in the Supplementary
file. Briefly, for the present study, we have included up to
5672 individuals from the 1958BC, 8520 participants from
the HRS and 404,648 individuals from UK Biobank.
Biomarker information and disease classification
Details on anthropometric data and biomarkers available from
each of the studies are provided in Supplementary Table 1 and
laboratory procedures are detailed in Supplementary methods.
For the HRS, details of biomarkers are provided in the HRS
documentation (http://hrsonline.isr.umich.edu/modules/meta/
bio2008/desc/Biomarker2006and2008.pdf). For the UK Bio-
bank, details of anthropometric and biochemical parameters
can be found in the following links: https://biobank.ndph.ox.
ac.uk/ukb/ukb/docs/Anthropometry.pdf and https://biobank.
ndph.ox.ac.uk/showcase/refer.cgi?id=1227, respectively. In
the UK Biobank, T2D cases were identified using the relevant
first occurrence data fields (Supplementary file), which were
generated by combining information from primary care data,
hospital inpatient data, mortality data and self-reported medi-
cal conditions reported at the baseline or follow-ups. CVD
events were ascertained from the hospital inpatient data and
mortality data, and were identified using ICD codes
(Supplementary file).
Milk intake
Information on milk intake was available from the 1958BC
and the UK Biobank. For the 1958BC, milk intake variable
was derived from the 45 years biomedical survey and based
on the question “how often do you drink milk alone or in
milky drinks”. In the UK Biobank, milk intake was derived
from a question “What type of milk do you mainly use?”
included in the touchscreen questionnaire (http://biobank.
ctsu.ox.ac.uk/crystal/refer.cgi?id=100312).
Genotyping and SNP selection
SNP rs4988235 was genotyped in all three cohorts. For
1958BC, this SNP was derived from genome-wide asso-
ciation study (GWAS) data (N= 2500 from Illumina Infi-
nium 550 K chip, N= 3000 from Affymetrix 6.0 platform).
For HRS, the DNA samples were genotyped at the Center
for Inherited Disease Research using the Illumina Huma-
nOmni2.5-4v1 array and using the calling algorithm Gen-
omeStudio version 2011.2, Genotyping Module 1.9.4 and
GenTrain version 1.0. For the UK Biobank, samples were
genotyped at the Affymetrix Research Services Laboratory
in Santa Clara, California, USA. Axiom Array plates were
processed on the Affymetrix GeneTitan® Multi-Channel
(MC) Instrument. Further details of DNA analysis can be
found in the Supplementary file.
Consortia-based studies
We have also used the summary statistics from other
consortia-based studies for the meta-analysis. We used
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GIANT [25] (N up to 327,665) for BMI, waist-to-hip ratio,
and height; Global Lipids [26] (N up to 188,577) for lipid-
related traits; MAGIC [27] (N up to 22,293) for diabetes-
related traits; ICBP [29] (N= 697,307) for systolic and
diastolic blood pressures, respectively; DIAGRAM [30]
(N= 34,840 cases and 114,981 controls) for T2D; CAR-
DIOGRAM [31] (N= 22,233 cases and 64,762 controls)
for coronary artery disease (CAD); and EPIC-InterAct [32]
(N= 12,722) for estimates of the LCT variant-milk intake
association.
Statistical analysis
Systolic (SBP) and diastolic (DBP) blood pressures were
calculated by averaging 2 BP measurements, and for indi-
viduals taking BP-lowering medication in the 1958BC,
HRS and the UK Biobank, we adjusted for the medication
use by adding 15 and 10 mm Hg to SBP and DBP,
respectively [28]. Pulse pressure (PP) was calculated as SBP
minus DBP. For participants on lipid-lowering medication,
we adjusted for their medication use by dividing their bio-
marker concentrations by a biomarker-specific correction
factor (0.68 for LDL-C, 1.05 for HDL-C, 0.75 for total
cholesterol, 0.87 for triglycerides, 1.21 for CRP, and 1.04
for HbA1c), which was obtained from the UK Biobank
[33]. In the analysis related to HbA1c, we have also
adjusted for anti-diabetic mediation use in the regression
model. The primary data analyses in 417,236 individuals
assumed an additive genetic model to be consistent with
look-up results from consortia-based studies. However, we
had also analysed the data under a recessive model, with
participants bearing ‘CT’ and ‘TT’ combined and ‘CC’
homozygotes as the reference, wherever appropriate. Chi-
square test was used to assess whether the genotype fre-
quencies were in Hardy-Weinberg Equilibrium (1958BC,
P= 0.522; HRS, P < 0.0001; UK Biobank, P= 0.088). The
genetic associations with the continuous outcomes were
examined using linear regression, with models adjusted for
gender, BMI, assessment centre, SNP array and region of
residence (1958BC) or principal components (HRS and UK
Biobank) to account for population stratification. All cardio-
metabolic traits [except SBP, DBP and glycated hae-
moglobin (HbA1c)] were inverse-normal-transformed to be
consistent with the look-up results from consortia. The data
from the 1958BC, HRS, the UK Biobank and consortia
were meta-analysed using the random effects meta-analysis
where estimates were available for at least two studies
(Supplementary Table 1). To quantify the causal effects of
milk intake, estimates of LCT-cardio-metabolic-traits asso-
ciations from the meta-analysis were taken forward for the
MR analysis, where the causal effect was estimated using
the instrumental variable ratio method, with the estimate of
LCT-milk intake association taken from the EPIC-interAct
study [32]. For the instrument validation analysis, the LCT
gene variant was tested for its association with age, sex,
social or lifestyle factors such as annual income, education,
health status, smoking and alcohol and coffee consumption
(P value < 0.00625, Bonferroni corrected threshold con-
sidered statistically significant). We conducted all analyses
using STATA, version 14.1 (StataCorp LP, College Station,
Texas, USA), with MR analyses performed using the
mrratio command in the mrrobust package [34].
To increase the statistical power, we used summary
statistics from consortia-based studies to meta-analyze with
the data from the three population-based studies. Results
from consortia meta-analyses were publicly available, and
in the GIANT [25], Global Lipids [26], MAGIC [27], ICBP
[29], DIAGRAM [30] and CARDIOGRAM [31], each
study had performed the association analyses assuming an
additive genetic model.
Results
Association of the LCT gene variant with milk intake
Table 1 shows the frequency of milk consumption stratified
based on gender, BMI and LCT gene variant. The odds of
consuming milk was higher for the ‘T’ allele carriers of the
LCT variant (SNP rs4988235) compared to the CC homo-
zygotes (OR: 2.14, 95% CI: 1.57–2.93, P= 1.68 × 10−6 for
the 1958BC; OR 1.21, 95% CI: 1.09–1.34, P= 3.0 × 10−4
for the UK Biobank). In the UK biobank, 1.83% of ‘TT’
carriers followed a lactose free diet compared to 1.77% and
2.40% in CT and CC carriers, respectively (P= 7.6 × 10−5).
The observed patterns of milk consumption varied strongly
by age, sex, social or lifestyle factors such as annual
income, education, health status, smoking and alcohol and
coffee consumption, while no notable imbalances were
observed by LCT genotype (Supplementary Table 2). Fur-
thermore, check against the GWAS catalogue (https://www.
ebi.ac.uk/gwas/), confirmed the association between LCT
rs4988235 and BMI (P= 2 × 10−6) [25], with no other
pleiotropic associations reported.
Phenotypic associations
In the 1958BC, there was no significant association between
high milk intake and cardiometabolic traits (P > 0.09)
(Table 2). In the UK Biobank, there was an association of
high milk intake with higher BMI (P= 3.72 × 10−124), SBP
(P= 1.06 × 10−6), DBP (P= 0.009), low-density lipopro-
tein cholesterol (LDL-C) (P= 1.20 × 10−19), TC (P=
2.75 × 10−12), triglycerides (P= 8.33 × 10−19), and C-
reactive protein (CRP) (P= 2.90 × 10−35) and lower
HDL-C (P= 8.31 × 10−6) and HbA1c (P= 7.96 × 10−14).
Evidence for a causal association between milk intake and cardiometabolic disease outcomes using a. . .
Meta-analysis of the data from 1958BC and UK Biobank
showed that there was an association of high milk intake
with lower HDL-C (P= 2.70 × 10−6) and higher triglycer-
ides (P= 0.001) and CRP (P= 2.60 × 10−30).
Association of the LCT gene variant with cardio-
metabolic traits
The ‘T’ allele indexing greater milk intake had a consistent
association with higher BMI in the UK Biobank (P=
2.73 × 10−7), GIANT consortium (P= 0.001), and the
meta-analysis (Pmeta-analysis= 4.68 × 10−12) (Table 2). In
contrast, LCT genotype was not associated with BMI
adjusted waist circumference (WC) (indicator for central
adiposity, Pmeta-analysis= 0.49).
All individual studies with available data showed an
inverse association between LCT genotype indexing greater
milk intake and lower serum LDL-C (Pmeta-analysis= 2.08 ×
10−26), HDL-C (Pmeta-analysis= 9.40 × 10−13), and total
cholesterol concentrations (Pmeta-analysis= 2.38 × 10−36)
(Table 2). None of the genetic associations between the ‘T’
allele indexing higher milk intakes and SBP, DBP, and
HbA1c were statistically significant (Pmeta-analysis > 0.11).
Information for CRP was only available for the 1958BC and
UK Biobank (Pmeta-analysis= 0.49).
Analyses in the UK Biobank confirmed the association
between LCT variant and a higher total body fat percentage
(P= 1.63 × 10−7), with a consistent association with higher
fat-% noted across all indicators of regional fat distribution
(Table 3). The estimates from these genetic associations
were used in the IV ratio analysis, which confirmed the
causal association of high milk intake with higher total body
fat (P= 2.40 × 10−4), leg fat (P= 2.59 × 10−4), arm fat
(P= 4.27 × 10−4) and trunk fat (P= 3.01 × 10−4).
In the UK Biobank, there was an association of the ‘T’
allele with T2D (P= 0.007), where ‘T’ allele carriers had 11%
lower risk of diabetes; but the associations of LCT variant with
CVD was not statistically significant (P= 0.302) (Table 4).
However, in consortia look-up, there was no evidence for the
association of LCT variant with T2D in the DIAGRAM
Table 1 Frequency of milk consumption stratified based on gender, body mass index (BMI) and gene variant.

























2.023 × 10−283 – –
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10 (37.04%) 17 (62.96%) 307
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1718 (84.84 %) – –
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LCT gene variant (additive model)














7.02 × 10−14 146 (19–225) 2.00 × 10−7
LCT gene variant (recessive model)









2.104 × 10−14 – –
aData are expressed as median (quartile 1–quartile 4).
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consortium (P= 0.201) but there was an association with
CAD in the CARDIoGRAM consortium (P= 0.030), where
‘T’ allele carriers had 14% lower risk of CAD.
Using the estimates taken from the results of meta-
analysis in Table 2 and estimates of the LCT variant-milk
intake association from the EPIC-interAct study (https://ca
re.diabetesjournals.org/content/42/4/568.long), [32] the MR
analysis confirmed the causal association of the genetically
instrumented high milk intake with higher BMI (P= 3.60 ×
10−5) and lower LDL-C (P= 3.60 × 10−6), total cholesterol
(P= 1.90 × 10−6) and HDL-C (P= 3.00 × 10−5) (Fig. 1).
Discussion
Our large-scale meta-analysis in up to 1,904,220 partici-
pants demonstrates that ‘T’ allele of the LCT SNP
rs4988235 indexing greater milk intake is significantly
associated with CVD-related risk factors such as higher
BMI and lower TC and LDL-C concentrations. Further-
more, using a two-sample MR analysis, we confirmed the
causality between genetically instrumented high milk intake
and higher BMI and lower LDL-C, total cholesterol and
HDL-C. In summary, our MR study represents an extensive
exploration of the LCT gene variant for associations with
milk intake and cardio-metabolic traits which is strength-
ened by the use of large datasets and consortia-based stu-
dies. Given the existing controversies between high milk
intake and CVD risk, our MR analysis will have significant
public health implications.
As an exposure, dairy milk is relatively complex, and in
addition to calcium, dairy products constitute an important
dietary source of protein and primarily saturated fat. Several
intervention studies have investigated the association between
dairy consumption and cardiovascular risk factors such as lipid
outcomes [9, 35, 36]. However, most of the studies have been
focused on comparing different types of milk (i.e. low fat vs.
high fat), while there are only a few studies investigating the
effects of milk per se. In addition, most of the studies were
small with short duration and lacked adequate control groups,
control of dietary composition and compliance measures. For
instance, a crossover feeding study in eight men showed that
the mean total and LDL-C were 7% and 11% lower, respec-
tively, after 6 weeks consumption of a controlled low fat diet
containing skim milk, compared to whole milk, suggesting
that reducing milk fat consumption led to more favourable
lipid profiles [9]. In addition, a few studies have also shown
that skim milk appeared to have advantages on lowering
cholesterol levels over whole milk or full cream milk [37, 38];
however, there was no effect on serum triglycerides [37]. On
the other hand, studies that compared the effect of isoenergetic
amounts of milk, cheese and butter on lipid outcomes showed
that total cholesterol concentration was significantly lower
after cheese than butter diet [35, 36]; however, a differential
effect of fat in milk and butter was not confirmed [36]. In
addition, a few prospective cohort studies have failed to show
that higher intakes of milk and dairy products, regardless of
milk fat levels, are associated with an increased risk of CVD-
related outcomes. Hence, it is still not clear whether it is the fat
content in dairy products that is contributing to the lower
cholesterol levels or it is due to an unknown ‘milk factor’.
Given the difficulties to assess the biological effects of dairy
milk per se, we used the LCT gene variant (rs4988235) as an
instrument to examine the causal association between milk
intake and lipid outcomes, as genetic associations are less
prone to confounding and free from reverse causation [39].
Table 4 Association of milk intake with cardiovascular diseases and
type 2 diabetes.
Phenotypes Ncases/Ncontrols OR
a 95% CI P value
DIAGRAM




Coronary artery disease 22,233/64,762 0.86 0.75–0.99 0.030
UK Biobank






CARDIoGRAM Coronary ARtery DIsease Genome-wide Replication
and Meta-analysis, DIAGRAM DIAbetes Genetics Replication And
Meta-analysis, OR odds ratio, CI confidence intervals.
aEffects are presented as odds ratios and 95% confidence intervals, per
50 g milk intake.
Table 3 Milk intake and body fat distribution in the UK Biobank.
N Beta ± SE P value
Total body fat
Phenotypic 398,654 0.086 ± 0.005 8.38E−76
Genetic 369,696 0.011 ± 0.002 1.63E−07
IV ratio (per 50 g milk intake) 369,696 0.031 ± 0.009 2.40E−04
Leg fat
Phenotypic 398,853 0.078 ± 0.004 1.59E−95
Genetic 369,879 0.009 ± 0.002 2.18E−07
IV ratio (per 50 g milk intake) 369,879 0.025 ± 0.007 2.59E−04
Arm fat
Phenotypic 398,799 0.084 ± 0.005 1.46E−71
Genetic 369,834 0.010 ± 0.002 1.37E−06
IV ratio (per 50 g milk intake) 369,834 0.029 ± 0.008 4.27E−04
Trunk fat
Phenotypic 398,639 0.095 ± 0.006 1.67E−64
Genetic 369,683 0.012 ± 0.002 3.92E−07
IV ratio (per 50 g milk intake) 369,683 0.036 ± 0.01 3.01E−04
Evidence for a causal association between milk intake and cardiometabolic disease outcomes using a. . .
Our study using LCT gene variant as a genetic instrument
confirmed the causal association between high milk con-
sumption and lower TC and LDL-C in the combined meta-
analysis. While the RCTs supplementing whole milk into the
diet either lowered or failed to alter TC or LDL-C
[37, 38, 40, 41], our large-scale study suggests an inverse
association between high milk consumption and TC.
Some of the explanations for the lower cholesterol levels in
response to high milk intake are as follows. Firstly, calcium
and lactose in the milk have been shown to affect lipid
metabolism where dietary lactose can affect lipaemia by
enhancing calcium absorption and that the administration of a
high amount of lactose results in decreased cholesterol content
in humans [42]. Secondly, compared to other dairy products,
milk is generally lower in fat and is also possible, that in order
to increase their calcium intakes, individuals who are lactose
intolerant tend to use more high fat dairy products such as
cheese and many yogurts as these are generally better tolerated
[43]. Thirdly, it is possible that dietary calcium intake may
increase excretion of bile acids leading to the regeneration of
bile acids from hepatic cholesterol and, eventually, resulting in
the lowering of cholesterol concentrations [44]. Lastly, it could
also be an outcome of gut microbial fermentation of indiges-
tible carbohydrates, that are capable of altering cholesterol
synthesis and disrupting enterohepatic circulation, thereby
lowering cholesterol levels [45].
Several MR studies have been carried out examining the
causal relationship between genetically instrumented milk
intake and cardio-metabolic traits. While studies have shown
associations of the LCT gene variant with obesity [46–49],
abdominal obesity [50], diabetes [51], metabolic syndrome
[46, 51] and their related traits such as BMI [46–49], WC [48],
fat percentage [47] and fasting glucose [52] a few studies have
failed to confirm these associations [16, 21, 50, 52, 53]. These
inconsistencies could be because of the differences in the
sample size, ethnicities, outcome measures and study design.
To address some of these issues, we have used a large sample
size (N= 417,236) from three population-based studies
focussing on Caucasian populations from the UK and the US
in a cross-sectional study design. In addition, we have used the
summary statistics from consortia-based studies (N up to
1,077,312) and based our inferences on consistent association
seen across the different large-scale studies included in our
analyses. While the phenotypic associations showed a sig-
nificant heterogeneity due to differences in the measurement of
milk intake across the studies, there was no heterogeneity in
the genetic associations, which suggests the significance of
using MR studies to explore causal relationships.
The association between milk intake and BMI has been
explored in several studies. The National Health and Nutrition
Examination Survey (NHANES) in 1493 children (2–4 years)
showed that milk had a more consistent positive association
Fig. 1 Mendelian Randomization (MR) estimates for the associa-
tion between milk intake and cardio-metabolic traits. Using the
estimates taken from the results of meta-analysis in Table 2 and esti-
mates of the LCT variant-milk intake association from the EPIC-
interAct study, the MR analysis showed a causal association of the
genetically instrumented high milk intake with higher BMI (P=
3.60 × 10−5) and lower LDL-C (P= 3.60 × 10−6), total cholesterol
(P= 1.90 × 10−6) and HDL-C (P= 3.00 × 10−5). Differences are
shown as SD increase in the outcome with the exception of SBP
(mmHg), DBP (mmHg), and HbA1c (%). * WC adjusted for BMI. SD
standard deviation, BMI body mass index, SBP systolic blood pres-
sure, DBP diastolic blood pressure, HDL-C high density lipoprotein
cholesterol, LDL-C low density lipoprotein cholesterol, HbA1c gly-
cated haemoglobin, CRP C-reactive protein, CI confidence interval.
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with BMI than other dairy products [7]. This finding was
confirmed in the Early Childhood Longitudinal Survey in
8950 children which also showed that higher milk consump-
tion was associated with higher z-scores of BMI at 4 years of
age [54]. In contrast, a longitudinal study in 19,352 Swedish
women (40–55 years) showed that milk consumption was
inversely associated with weight gain, where participants who
consumed at least one serving of milk per day had an odds
ratio of 0.85 (95% CI: 0.73, 0.99) [55]. Similarly, a study in
1001 adolescents also showed an inverse association between
milk intake and BMI [56]. Despite large samples, the findings
have been inconsistent. However, genetic studies including a
meta-analysis have shown that the ‘T’ allele carriers of the
SNP rs4988235 (LP genotype) had higher BMI [51, 57],
which is in line with our findings in the GIANT consortium
(N= 327,665) and combined meta-analysis (N= 417,236),
where the ‘T’ allele carriers had 0.02 and 0.015 kg/m2 higher
BMI compared to the ‘CC’ homozygotes, respectively. Our
study confirmed the causal association of the genetically
instrumented milk intake with BMI and also body fat dis-
tribution (total body fat, leg fat, arm fat and trunk fat).
Despite some evidence from observational studies, and a
smaller MR study [51] we did not find strong evidence for an
association between milk intake and T2D or the regulation of
long-term glucose metabolism indicated by HbA1c. A recent
MR study in 21,820 European individuals has also failed to
provide a genetic evidence for the association of milk intake
with T2D [32]. Even though our study failed to show an
association with T2D in the DIAGRAM consortium, we did
find a significant association of the high milk intake ‘T’ allele
with decreased T2D risk and lower HbA1c concentration in
the UK Biobank cohort and with higher fasting insulin and
HOMA-IR in the MAGIC consortium. These findings are in
accordance with the study in 272 non-diabetic Caucasian
women where those in the highest quartile of dairy con-
sumption had higher HOMA-IR values than those in the
lowest quartile [58]. In contrast, a prospective study in 2091
Chinese men and women showed that the dairy consumption
was significantly associated with reduced risk of T2D [59]. In
addition, a systematic review based on five studies that
assessed the effect of dairy consumption on insulin sensitivity
demonstrated that four studies showed a positive effect of
dairy consumption on insulin sensitivity while one study failed
to show any effect [60]. A recent study in 147,812 individuals
from 21 countries has also shown higher intake of whole fat
dairy was associated with lower incidence of diabetes [61].
These discrepancies could be because of the use of various
dairy products rather than milk per se, small sample size and
gender differences in sample selection. In contrast to our
genetic associations, a study in 3575 Europeans failed to show
an effect of the LP genotype with insulin level but showed an
association with T2D [51]. Further large-scale meta-analyses
including a broader range of diabetes-related traits may help to
overcome these discrepancies in genetic associations.
In accordance with several randomised trials [5, 62, 63], our
MR study also did not provide any evidence for a causal effect
of high milk intake on CRP, an inflammatory biomarker.
However, a few human intervention studies have shown a
significant effect of milk consumption on other inflammatory
biomarkers. An RCT in 58 Korean adults with metabolic
syndrome investigated the effects of low-fat milk consumption
on inflammatory and atherogenic biomarkers and found
favourable changes for blood pressure and atherogenic mar-
kers, such as sVCAM‐1, sICAM‐1 and endothelin‐1, espe-
cially in those with hypertension or hypertriglyceridaemia
[64]. Another intervention study in 42 smokers showed that
non-supplemented milk (without fruit/vegetable extracts and
vitamin C) significantly reduced inflammatory cytokines such
as IL-6, IL-1beta and TNFA [65]. These favourable changes
could be because the milk is rich in elements such as calcium,
magnesium and potassium that help regulate blood pressure.
In addition, casein and whey protein present in the milk are
also considered as active biological peptides that inhibit
angiotensin-I converting enzyme, an important factor in reg-
ulating blood pressure. Whether milk consumption exerts anti-
inflammatory effects is presently questionable given the dis-
crepancies in the findings from multiple studies and hence,
further demonstration is required through well-designed and
sufficiently powered studies.
One of the main strengths of our study is the large sample
size. Besides using 1958BC (N= 5672), HRS (N= 8520) and
the UK Biobank (N= 404,648), we have used the summary
statistics from various consortia such as GIANT (N=
327,665), Global Lipids (N= 188,577), MAGIC (N=
22,293), ICBP (N up to 697,307), DIAGRAM (N= 34,840
cases and 114,981 controls) (T2D) and CARDIOGRAM
(22,233 cases and 64,762 controls) to replicate our findings.
Previous studies have shown conflicting findings regarding the
association between high milk consumption and cardio-
metabolic traits due to unknown confounding factors. How-
ever, our study has used the LCT gene variant as an instru-
ment, which is unlikely to be affected by confounding factors,
to establish the causal association. The use of large samples
from the discovery cohorts, various consortia and genetic
instrument has enabled us to make firm conclusions on the
causal association between milk intake and cardio-metabolic
traits such as BMI, BP, CAD, and lipids. Some of the lim-
itations of the study include the lack of available information
on gastro-intestinal diseases of the study participants and the
type of milk (skim or whole) and the differences in the mea-
surement of milk intake variable.
In conclusion, our study confirms the causal association
between genetically instrumented high milk consumption
and cardio-metabolic phenotypes, where the ‘T’ allele was
Evidence for a causal association between milk intake and cardiometabolic disease outcomes using a. . .
associated with higher BMI and lower LDL-C and TC. Large
intervention trials are needed to establish the causal link
between high milk consumption and cardio-metabolic phe-
notypes before changes in dairy consumption could be
recommended for the prevention of cardiometabolic traits.
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